Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Am J Trop Med Hyg ; 78(2): 289-93, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18256431

RESUMO

Laboratory tools to monitor infection burden are important to evaluate progress and determine endpoints in programs to eliminate lymphatic filariasis. We evaluated changes in Wuchereria bancrofti microfilaria, filarial antigen and Bm14 antibody in individuals who participated in a five-year mass drug administration trial in Papua New Guinea. Comparing values before treatment and one year after four annual treatments, the proportion of microfilaria positive individuals declined to the greatest degree, with less marked change in antibody and antigen rates. Considering children as sentinel groups who reflect recent transmission intensity, children surveyed before the trial were more frequently microfilaria and antibody positive than those examined one year after the trial stopped. In contrast, antigen positive rates were similar in the two groups. All infection indicators continued to decline five years after cessation of mass drug administration; Bm14 antibody persisted in the greatest proportion of individuals. These data suggest that Bm14 antibody may be a sensitive test to monitor continuing transmission during and after mass drug administration aimed at eliminating transmission of lymphatic filariasis.


Assuntos
Anticorpos Anti-Helmínticos/sangue , Antígenos de Helmintos/sangue , Antiparasitários/uso terapêutico , Filariose Linfática/prevenção & controle , Wuchereria bancrofti/imunologia , Animais , Antiparasitários/administração & dosagem , Criança , Pré-Escolar , Dietilcarbamazina/uso terapêutico , Quimioterapia Combinada , Filariose Linfática/tratamento farmacológico , Filariose Linfática/epidemiologia , Filariose Linfática/imunologia , Seguimentos , Humanos , Lactente , Ivermectina/administração & dosagem , Ivermectina/uso terapêutico , Papua Nova Guiné/epidemiologia , Wuchereria bancrofti/isolamento & purificação
2.
Filaria J ; 2(1): 14, 2003 Sep 14.
Artigo em Inglês | MEDLINE | ID: mdl-14525619

RESUMO

The spatial variation of Wuchereria bancrofti and Plasmodium falciparum infection densities was measured in a rural area of Papua New Guinea where they share anopheline vectors. The spatial correlation of W. bancrofti was found to reduce by half over an estimated distance of 1.7 km, much smaller than the 50 km grid used by the World Health Organization rapid mapping method. For P. falciparum, negligible spatial correlation was found. After mass treatment with anti-filarial drugs, there was negligible correlation between the changes in the densities of the two parasites.

3.
N Engl J Med ; 347(23): 1841-8, 2002 Dec 05.
Artigo em Inglês | MEDLINE | ID: mdl-12466508

RESUMO

BACKGROUND: The global initiative to eradicate bancroftian filariasis currently relies on mass treatment with four to six annual doses of antifilarial drugs. The goal is to reduce the reservoir of microfilariae in the blood to a level that is insufficient to maintain transmission by the mosquito vector. METHODS: In nearly 2500 residents of Papua New Guinea, we prospectively assessed the effects of four annual treatments with a single dose of diethylcarbamazine plus ivermectin or diethylcarbamazine alone on the incidence of microfilariae-positive infections, the severity of lymphatic disease, and the rate of transmission of Wuchereria bancrofti by mosquitoes. Random assignment to treatment regimens was carried out according to the village of residence, and villages were categorized as having moderate or high rates of transmission. RESULTS: The four annual treatments with either drug regimen were taken by 77 to 86 percent of the members of the population who were at least five years old; treatments were well tolerated. The proportion with microfilariae-positive infections decreased by 86 to 98 percent, with a greater reduction in areas with a moderate rate of transmission than in those with a high rate. The respective aggregate frequencies of hydrocele and leg lymphedema were 15 percent and 5 percent before the trial began, and 5 percent (P<0.001) and 4 percent (P=0.04) after five years. Hydrocele and leg lymphedema were eliminated in 87 percent and 69 percent, respectively, of those who had these conditions at the outset. The rate of transmission by mosquitoes decreased substantially, and new microfilariae-positive infections in children were almost completely prevented over the five-year study period. CONCLUSIONS: Annual mass treatment with drugs such as diethylcarbamazine can virtually eliminate the reservoir of microfilariae and greatly reduce the frequency of clinical lymphatic abnormalities due to bancroftian filariasis. Eradication may be possible in areas with moderate rates of transmission, but longer periods of treatment or additional control measures may be necessary in areas with high rates of transmission.


Assuntos
Dietilcarbamazina/uso terapêutico , Filariose Linfática/tratamento farmacológico , Filaricidas/uso terapêutico , Ivermectina/uso terapêutico , Adolescente , Adulto , Animais , Criança , Pré-Escolar , Culicidae/parasitologia , Dietilcarbamazina/administração & dosagem , Dietilcarbamazina/efeitos adversos , Reservatórios de Doenças , Esquema de Medicação , Quimioterapia Combinada , Filariose Linfática/epidemiologia , Filariose Linfática/prevenção & controle , Filariose Linfática/transmissão , Filaricidas/administração & dosagem , Filaricidas/efeitos adversos , Humanos , Ivermectina/efeitos adversos , Linfedema/tratamento farmacológico , Linfedema/etiologia , Masculino , Papua Nova Guiné/epidemiologia , Estudos Prospectivos , Hidrocele Testicular/tratamento farmacológico , Hidrocele Testicular/etiologia , Wuchereria bancrofti/isolamento & purificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA